| Multiple Myeloma
Kyprolis vs Xgeva
Side-by-side clinical, coverage, and cost comparison for multiple myeloma.Deep comparison between: Kyprolis vs Xgeva with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXgeva has a higher rate of injection site reactions vs Kyprolis based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xgeva but not Kyprolis, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Kyprolis
Xgeva
At A Glance
IV infusion
Once or twice weekly
Proteasome inhibitor
SC injection
Every 4 weeks
RANKL inhibitor
Indications
- Multiple Myeloma
- Multiple Myeloma
- Metastatic malignant neoplasm to bone
- Giant Cell Tumor of Bone
- Humoral hypercalcemia of malignancy (disorder)
Dosing
Multiple Myeloma 20/70 mg/m2 IV once weekly as a 30-minute infusion on Days 1, 8, and 15 of each 28-day cycle (in combination with dexamethasone, daratumumab plus dexamethasone, or daratumumab and hyaluronidase-fihj plus dexamethasone); start at 20 mg/m2 on Cycle 1, Day 1, escalate to 70 mg/m2 on Cycle 1, Day 8 if tolerated.
Multiple Myeloma 20/56 mg/m2 IV twice weekly as a 30-minute infusion on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycle (as monotherapy or in combination with dexamethasone, daratumumab plus dexamethasone, daratumumab and hyaluronidase-fihj plus dexamethasone, or isatuximab plus dexamethasone); start at 20 mg/m2 on Cycle 1, Days 1 and 2, escalate to 56 mg/m2 on Cycle 1, Day 8 if tolerated.
Multiple Myeloma 20/27 mg/m2 IV twice weekly as a 10-minute infusion on Days 1, 2, 8, 9, 15, and 16 (Cycles 1-12) or Days 1, 2, 15, and 16 (Cycle 13+) of each 28-day cycle (as monotherapy or in combination with lenalidomide and dexamethasone); start at 20 mg/m2 on Cycle 1, Days 1 and 2, escalate to 27 mg/m2 on Cycle 1, Day 8 if tolerated.
Multiple Myeloma, Metastatic malignant neoplasm to bone 120 mg SC every 4 weeks in the upper arm, upper thigh, or abdomen.
Giant Cell Tumor of Bone, Humoral hypercalcemia of malignancy (disorder) 120 mg SC every 4 weeks with additional 120 mg doses on Days 8 and 15 of the first month of therapy, in the upper arm, upper thigh, or abdomen.
Contraindications
—
- Pre-existing hypocalcemia
- Known clinically significant hypersensitivity to Xgeva or denosumab products
Adverse Reactions
Most common (>=20%) Anemia, diarrhea, hypertension, fatigue, upper respiratory tract infection, thrombocytopenia, pyrexia, cough, dyspnea, insomnia
Serious Cardiac toxicities, acute renal failure, tumor lysis syndrome, pulmonary toxicity, pulmonary hypertension, venous thrombosis, infusion-related reactions, hemorrhage, hepatic toxicity and failure, thrombotic microangiopathy, posterior reversible encephalopathy syndrome, progressive multifocal leukoencephalopathy
Postmarketing Hemolytic uremic syndrome, hepatitis B virus reactivation, gastrointestinal perforation, pericarditis, cytomegalovirus infection
Most common (>=25%) Fatigue/asthenia, hypophosphatemia, nausea
Serious Dyspnea, osteonecrosis of the jaw, hypocalcemia, atypical subtrochanteric and diaphyseal femoral fracture, multiple vertebral fractures following treatment discontinuation
Postmarketing Severe symptomatic hypocalcemia (including fatal cases), severe symptomatic hypercalcemia following treatment discontinuation, hypersensitivity including anaphylactic reactions, severe musculoskeletal pain, lichenoid drug eruptions, alopecia
Pharmacology
Carfilzomib is a tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds to the N-terminal threonine-containing active sites of the 20S proteasome within the 26S proteasome, producing antiproliferative and proapoptotic effects in hematologic and solid tumor cells.
Xgeva is a RANKL inhibitor; it binds to RANKL, a protein essential for osteoclast formation, function, and survival, thereby preventing osteoclast-mediated bone resorption and modulating calcium release from bone in solid tumor bone metastases, multiple myeloma, giant cell tumor of bone, and hypercalcemia of malignancy.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Kyprolis
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Xgeva
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (9/12) · Qty limit (11/12)
UnitedHealthcare
Kyprolis
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Xgeva
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Kyprolis
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Xgeva
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAmgen Safety Net Foundation
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Xgeva.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
KyprolisView full Kyprolis profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.